Health services research at UNC is informing community-based outreach efforts in prostate cancer—including engagement with HBCUs and patient groups across North Carolina—by centering patient and community perspectives to identify and address the barriers that prevent evidence-based care from reaching those who need it most.
ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality compared with a historical ADT control—while its use of propensity score matching with an external phase 3 control arm represents a novel trial design that may inform future studies in rapidly evolving treatment landscapes.
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC.
In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
Rana R. McKay, MD, FASCO, shares results from the ARASEC study, which evaluated darolutamide plus ADT in mHSPC using a novel external control-arm design.
